Donald R. Branch

Dr. Donald R. Branch

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2012 in Transfusion
Verified
Journal Article
Closed access
PDF file
DLDanila Leontyev
Danila Leontyev
YKYulia Katsman
Yulia Katsman
XMXue‐Zhong Ma
Xue‐Zhong Ma
SMSylvia Miescher
Sylvia Miescher
FKFabian Käsermann
Fabian Käsermann
DBDonald R. Branch
Donald R. Branch

7 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SDSonam Dubey
Sonam Dubey
SHStefan Heinen
Stefan Heinen
SKSlavica Krantic
Slavica Krantic
JMJoAnne McLaurin
JoAnne McLaurin
DBDonald R. Branch
Donald R. Branch
IAIsabelle Aubert
Isabelle Aubert
Significance: The efficacy of immunotherapy in Alzheimer’s disease is limited, partly because antibodies, administered peripherally, have poor access to the brain. Focused ultrasound (FUS) with microbubbles allows the passage of antibodies from the blood to the brain. In a mouse model of Alzheimer’s disease, antibodies administered in the blood, with and without FUS, reduced amyloid pathology. In contrast, FUS was required to deliver sufficient antibodies to the hippocampus and effectively promote neurogenesis. Neurogenesis, a regenerative process involved in memory functions, is impaired in Alzheimer’s disease. Putative contributors to the stimulation of neurogenesis include a decrease in the proinflammatory cytokine TNF-α. FUS holds potential to increase the efficacy of immunotherapy for Alzheimer’s disease.

14 July 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
DBDonald R. Branch
Donald R. Branch

Verified
Journal Article
Open access
PDF file
MLMelika Loriamini
Melika Loriamini
CCChristine Cserti-Gazdewich
Christine Cserti-Gazdewich
DBDonald R. Branch
Donald R. Branch
Autoimmune hemolytic anemias (AIHAs) are conditions involving the production of antibodies against one’s own red blood cells (RBCs). These can be primary with unknown cause or secondary (by association with diseases or infections). There are several different categories of AIHAs recognized according to their features in the direct antiglobulin test (DAT). (1) Warm-antibody AIHA (wAIHA) exhibits a pan-reactive IgG autoantibody recognizing a portion of band 3 (wherein the DAT may be positive with IgG, C3d or both). Treatment involves glucocorticoids and steroid-sparing agents and may consider IVIG or monoclonal antibodies to CD20, CD38 or C1q. (2) Cold-antibody AIHA due to IgMs range from cold agglutinin syndrome (CAS) to cold agglutin disease (CAD). These are typically specific to the Ii blood group system, with the former (CAS) being polyclonal and the latter (CAD) being a more severe and monoclonal entity. The DAT in either case is positive only with C3d. Foundationally, the patient is kept warm, though treatment for significant complement-related outcomes may, therefore, capitalize on monoclonal options against C1q or C5. (3) Mixed AIHA, also called combined cold and warm AIHA, has a DAT positive for both IgG and C3d, with treatment approaches inclusive of those appropriate for wAIHA and cold AIHA. (4) Paroxysmal cold hemoglobinuria (PCH), also termed Donath–Landsteiner test-positive AIHA, has a DAT positive only for C3d, driven upstream by a biphasic cold-reactive IgG antibody recruiting complement. Although usually self-remitting, management may consider monoclonal antibodies to C1q or C5. (5) Direct antiglobulin test-negative AIHA (DAT-neg AIHA), due to IgG antibody below detection thresholds in the DAT, or by non-detected IgM or IgA antibodies, is managed as wAIHA. (6) Drug-induced immune hemolytic anemia (DIIHA) appears as wAIHA with DAT IgG and/or C3d. Some cases may resolve after ceasing the instigating drug. (7) Passenger lymphocyte syndrome, found after transplantation, is caused by B-cells transferred from an antigen-negative donor whose antibodies react with a recipient who produces antigen-positive RBCs. This comprehensive review will discuss in detail each of these AIHAs and provide information on diagnosis, pathophysiology and treatment modalities.

1 June 2010 in Cancer Biology & Therapy
Verified
Journal Article
Open access
MSManujendra N. Saha
Manujendra N. Saha
HJHua Jiang
Hua Jiang
JJJennifer Jayakar
Jennifer Jayakar
DRDonna Reece
Donna Reece
DBDonald R. Branch
Donald R. Branch
CHChang Hong
Chang Hong
Mutliple myeloma (MM) has one of the poorest prognoses of the haematological malignancies and novel therapeutic approaches are needed. Therapeutic induction of p53 might be important to evaluate th...

15 April 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SSSpirig Spirig
Spirig Spirig
ICIan Keith Campbell
Ian Keith Campbell
SKSandra Koernig
Sandra Koernig
CCChao-Guang Chen
Chao-Guang Chen
BLBonnie J. B. Lewis
Bonnie J. B. Lewis
AZAdrian W. Zuercher
Adrian W. Zuercher
Activation of Fc receptors and complement by immune complexes is a common important pathogenic trigger in many autoimmune diseases and so blockade of these innate immune pathways may be an attractive target for treatment of immune complex-mediated pathomechanisms. High-dose IVIG is used to treat autoimmune and inflammatory diseases, and several studies demonstrate that the therapeutic effects of IVIG can be recapitulated with the Fc portion. Further, recent data indicate that recombinant multimerized Fc molecules exhibit potent anti-inflammatory properties. In this study, we investigated the biochemical and biological properties of an rFc hexamer (termed Fc-μTP-L309C) generated by fusion of the IgM μ-tailpiece to the C terminus of human IgG1 Fc. Fc-μTP-L309C bound FcγRs with high avidity and inhibited FcγR-mediated effector functions (Ab-dependent cell-mediated cytotoxicity, phagocytosis, respiratory burst) in vitro. In addition, Fc-μTP-L309C prevented full activation of the classical complement pathway by blocking C2 cleavage, avoiding generation of inflammatory downstream products (C5a or sC5b-9). In vivo, Fc-μTP-L309C suppressed inflammatory arthritis in mice when given therapeutically at approximately a 10-fold lower dose than IVIG, which was associated with reduced inflammatory cytokine production and complement activation. Likewise, administration of Fc-μTP-L309C restored platelet counts in a mouse model of immune thrombocytopenia. Our data demonstrate a potent anti-inflammatory effect of Fc-μTP-L309C in vitro and in vivo, likely mediated by blockade of FcγRs and its unique inhibition of complement activation.